-
In late February 2026, CVS Health warned that pending Tennessee legislation banning combined ownership of pharmacies and pharmacy benefit managers could force closure of all 134 of its state stores, MinuteClinics, and related operations, threatening thousands of jobs and patient access to care.
-
This pushback against CVS's vertically integrated model in Tennessee highlights growing regulatory scrutiny that could have wider implications for how large healthcare chains combine insurance, PBM, and retail pharmacy businesses.
-
We'll now examine how the Tennessee bill targeting CVS's integrated pharmacy and PBM model could reshape the company's broader investment narrative.
Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
CVS Health Investment Narrative Recap
To own CVS Health, you need to believe its integrated model across insurance, PBM, and retail care can still create value despite thin margins and policy risk. Right now, the key near term focus is whether management can stabilize profitability in health care delivery while keeping pharmacy and PBM earnings resilient. The Tennessee push against vertical integration underscores regulatory risk, but on its own it does not yet alter the main earnings catalyst or the biggest margin concerns.
Against this backdrop, CVS's plan to scale back its Medicare Advantage exposure and exit the Obamacare marketplace in 2026 is particularly important, because it speaks directly to the margin pressure and reimbursement uncertainty that have weighed on the Aetna insurance unit. While investors watch Tennessee as a test case for future regulation, the more immediate question is whether these portfolio changes can support the company's effort to rebuild returns and improve the quality of earnings.
But while the integrated model is central to many expectations, investors should also be aware that ...
Read the full narrative on CVS Health (it's free!)
CVS Health's narrative projects $445.1 billion revenue and $8.3 billion earnings by 2028. This requires 5.0% yearly revenue growth and a $3.8 billion earnings increase from $4.5 billion today.
Uncover how CVS Health's forecasts yield a $94.84 fair value , a 19% upside to its current price.
Exploring Other Perspectives
Five members of the Simply Wall St Community currently estimate CVS Health's fair value between about US$94.84 and US$289.26, highlighting how far apart individual views can be. Set against this wide spread, ongoing pressure on pharmacy reimbursement and medical benefit ratios reminds you to weigh these differing valuations against the underlying execution and policy challenges that could influence CVS's ability to improve returns.
Explore 5 other fair value estimates on CVS Health - why the stock might be worth just $94.84!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
-
A great starting point for your CVS Health research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
-
Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
-
We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
-
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
-
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it . Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CVS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
